Lama laba for copd update#
The 2021 update included information regarding the use of e-cigarettes as nicotine replacement, triple therapy, and how the SARS-CoV-2 virus impacted patients with COPD.
This supersedes previous guidance to use LAMA or LABA monotherapy first. The label also includes clinical data from the phase IV ASCENT study, which shows aclidinium therapy is effective at reducing COPD exacerbations.Īccording to Circassia Pharma, Duaklir is the only twice-daily LAMA/LABA in the US with COPD exacerbation data included in its prescribing information. The Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines classify a patient’s COPD and provide recommendations for first-line treatment. LABA/LAMA combination treatment is now recommended as the first-line option in patients requiring a long-acting bronchodilator, including those who are more symptomatic or at high exacerbation risk. The approval is based on data from three phase III studies: ACLIFORM, AUGMENT and AMPLIFY. The US FDA has approved twice-daily Duaklir, a fixed-dose combination LAMA/LABA for the maintenance treatment of COPD, according to manufacturer Circassia Pharmaceuticals.ĭuaklir is a fixed-dose combination of the LAMA aclidinium bromide (400 mcg) and LABA formoterol fumarate (12 mcg) and is administered twice-daily via AstraZeneca’s Pressair breath-actuated inhaler. Abstract: In chronic obstructive pulmonary disease (COPD), treatment with inhaled corticosteroids (ICSs) in combination with long acting beta-2-agonists (LABA) or LABA/long-acting muscarinic antagonists (LAMA) is used in order to reduce exacerbations.
0 kommentar(er)
